

## Business Results Summary for Q1 FY2026/03

We hereby present an overview of the progress in business operations and financial results for the cumulative first quarter period of FY2026.

### 1. Business Updates

#### 1) Drug Discovery

##### (1) Pipeline Progress

| Code      | Target Disease              | Update  |
|-----------|-----------------------------|---|
| PPMX-T003 | Polycythemia vera           | Domestic Phase I trial completed (June 2024). We are currently undertaking out-licensing activities.  |
|           | Aggressive NK-cell leukemia | <ul style="list-style-type: none"> <li>- Selected by AMED <sup>a)</sup> for its Drug Discovery Support Program for Orphan Drugs (FY2026/03).</li> <li>- The investigator-initiated Phase I/II trial expanded to 9 sites to accelerate patient enrollment.</li> </ul>  |
|           | (Other)                     | <ul style="list-style-type: none"> <li>- A co-authored paper with Hyogo Medical University on basic research for vascular remodeling was published.</li> <li>- A paper by Dr. Ryo Yanagiya at Osaka University proposing a revised model for cell cycle regulation by iron was published.</li> </ul>  |
| PPMX-T002 | Solid tumor                 | <ul style="list-style-type: none"> <li>- Radioisotope-labeled antibody: The radioisotope was switched from Yttrium-90 (<sup>90</sup>Y) to Actinium-225 (<sup>225</sup>Ac), and development of a new radioisotope-labeled antibody drug is underway. Preclinical evaluation of <sup>225</sup>Ac-PPMX-T002 was presented at the 41st Annual Meeting of the Japan DDS Society.</li> <li>- Early out-licensing activities with a focus on companies engaged in radiopharmaceuticals are ongoing.</li> </ul> |
| PPMX-T004 | Solid tumor                 | The optimal combination of payload and linker for ADC <sup>b)</sup> has been identified, and high anti-tumor efficacy was demonstrated in mouse studies. Preliminary toxicology studies are in progress.  |

## (2) Core Technology

A joint research collaboration has started with Institute of Science Tokyo, a national university, on antibody drug discovery using machine learning. This collaboration combines the computational analysis technology of Prof. Masashi Oue from the School of Computer Science at Institute of Science Tokyo with our proprietary antibody library. The aim is to rapidly select target antibodies. Synergy between computer analysis and biological experiments is expected to improve machine learning accuracy and streamline antibody selection processes.

## 2) Antibody Research Support

- Antibody screening and production services using VHH antibody <sup>c)</sup> libraries have commenced.

## 3) Antibody & Reagent Sales

- An anti-Exatecan antibody for ADC research and development was launched.
- An anti-GPR87 antibody for disease research was launched.

## 2. Financial updates

| Item      | Update  |
|-----------|---|
| Net Sales | ¥23,472 thousand (+ 12.5% YoY)                              |
|           | -Antibody research support : ¥3,050 thousand (+ 228.0% YoY) |
|           | -Antibody & reagent sales : ¥20,422 thousand (+ 2.5% YoY)   |

(End of Document)

Notes:

- "AMED" refers to the Japan Agency for Medical Research and Development, a Japanese government agency supporting medical R&D.  
Japan Agency for Medical Research and Development,
- "ADC" stands for antibody-drug conjugate, a type of antibody linked to a cytotoxic drug.
- "VHH antibody" is the variable domain of heavy-chain antibodies from camels, notable for small size and stability.